0001100682-25-000043
SEC filingRevenue declined modestly, operating margin improved in Q3 due to lower costs, but net income fell on investment losses; cautious client spending persists.
For the three months ended September 27, 2025, total revenue declined 0.5% to $1.0049 billion compared to $1.0098 billion in the prior-year quarter. Service revenue fell 2.9% to $808.0 million, while product revenue grew 11.0% to $196.8 million. Operating income improved 14.0% to $133.8 million, with operating margin expanding 170 bps to 13.3% from 11.6%, primarily due to lower severance costs and reduced unallocated corporate employee compensation. However, net income available to common shareholders decreased to $54.4 million from $68.7 million, driven by $21.1 million in net losses and impairments on venture capital and strategic equity investments versus $2.5 million in net gains in the prior year.
For the nine months, consolidated revenue was $3.021 billion, down 0.9% from $3.047 billion. Operating income fell 21.9% to $308.6 million (margin 10.2% vs. 13.0%), reflecting accelerated amortization from CDMO client relationship impairment, increased restructuring costs, and higher third-party legal and advisory fees. Net income declined 41.5% to $132.2 million, further pressured by $34.0 million in investment losses compared to prior-year net gains.
RMS revenue grew 7.9% in Q3 to $213.5 million, driven by Noveprim large research model sales and growth in China, with operating margin expanding 230 bps to 16.2%. DSA revenue decreased 2.3% to $600.7 million as cautious biopharma spending persisted; operating margin contracted slightly (10 bps) to 20.5%. Manufacturing revenue fell 3.1% to $190.7 million on weaker Biologics CDMO demand, though operating margin improved 50 bps to 20.9% due to lower severance and amortization. Segment operating margins for the nine months: RMS 17.8% (+170 bps), DSA 18.8% (-170 bps), Manufacturing 7.6% (-1,170 bps) due to accelerated amortization and restructuring.
Management expects restructuring actions to yield approximately $225 million in annualized cost savings, with ~$175 million impacting fiscal 2025. Additional initiatives announced in the November 2025 strategic review are expected to generate incremental net savings of $70 million annually, fully realized in 2026. The company plans to divest assets representing ~7% of estimated 2025 revenue. DSA backlog declined to $1.8 billion from $2.0 billion at year-end 2024, indicating ongoing demand headwinds. The financial impact of new tariffs and the FDA’s pilot program to reduce animal testing remains uncertain, but management plans to offset tariff costs through pricing. No formal numerical guidance was provided for revenue, earnings, or margins.
Cash and equivalents stood at $207.1M as of September 27, 2025, slightly up from $194.6M at year-end 2024. Total debt (including finance leases) was $2,201.4M, down $57.6M from $2,259.0M. The company maintains a $2.0B revolving credit facility with $665.5M drawn. Shareholders' equity decreased to $3,405.4M from $3,461.5M, mainly due to share repurchases. Inventory increased to $302.6M from $278.5M, driven by higher finished products.
Remaining performance obligations (RPO) totaled $649.3M, with approximately 50% expected to be recognized within 12 months. Deferred revenue was $280.2M (current $237.7M, long-term $42.5M). Customer contract deposits were $91.2M. No material purchase commitments were disclosed in the Notes.
During the nine months, the company repurchased 2.1 million shares for $350.0M under the $1.0B authorization, leaving $549.3M remaining. On October 29, 2025, a new $1.0B authorization replaced the prior plan. No dividends were declared. Net debt decreased by $57.6M. Capital expenditures totaled $130.2M, or 4.3% of revenue, down from $157.4M in the prior year period.
RMS revenue grew 7.9% YoY to $213.5M, with operating income up to $34.6M (16.2% margin). DSA revenue declined 2.3% to $600.7M, operating income $123.2M (20.5% margin). Manufacturing revenue fell 3.1% to $190.7M, operating income $39.9M (20.9% margin). Geographically, U.S. revenue was $537.6M (53.5% of total), Europe $277.7M (27.6%), Canada $116.8M (11.6%), Asia Pacific $51.7M (5.1%), and Other $21.1M (2.1%).
Operating cash flow (CFO) of $590.1 million exceeded net income of $134.1 million by a factor of 4.4x, indicating strong cash conversion driven by non-cash charges (depreciation of $325.0M, impairments, stock compensation). Working capital was a net use of $7.5M, with inventory build of $45.3M and other asset increases partially offset by higher payables and accrued compensation. Capital expenditures of $130.2M represent a capex intensity of 22% of CFO, down from 27% in the prior period. The company deployed significant cash to share repurchases ($360.6M) and debt repayments (net debt paydown of $70.6M after borrowings). Underlying free cash flow (CFO less capex) was $459.9M, covering repurchases by 1.3x. No dividends were paid. The substantial increase in share repurchases and debt reduction reflects confidence in cash generation, though the reliance on buybacks may signal limited organic reinvestment opportunities.